1) And if you read those medical studies a little more thoroughly
you’ll also discover the authors state (at least in both studies im aware of) the SERM-AI interaction is NOT clinically relevant
2) “Rebound” applies to bro science in a Petri dish. Otherwise you need to define “rebound” bc “saturation”, “neutralization” of the aromatase enzyme would be required based upon the phenomena you’ve outlined, and that process has not been described in the AI or aromasin literature.
3) Finally
@Blake111 you might want to outline your cycle contents and dosages bc
those two factors often have a significant impact on the timing of PCT, and that’s just as important at the drugs themselves, esp if lab are not used as a guideline
I do my own research and stated for him to so as well. There are many articles on the subject here is just 1. I wish I would not have replied to this post because I knew I would get hammered. http://theoncologist.alphamedpress.org/content/13/8/829.full (Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?)